NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
🟢 Neurosense Therapeutics is trading 12.1% up today after HC Wainwright initiated coverage with $8.00 target
Neurosense Therapeutics is trading 12.1% up at $0.45 after HC Wainwright initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price...
🟢 Neurosense Therapeutics is trading 9.56% up today after HC Wainwright initiated Buy-rated coverage
Neurosense Therapeutics is trading 9.56% up now at $0.44 after HC Wainwright initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price...
🟢 Neurosense Therapeutics is trading 8.69% up today after HC Wainwright initiated Buy-rated coverage
Neurosense Therapeutics is trading 8.69% up now at $0.45 after HC Wainwright initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price...
🟢 Neurosense Therapeutics is trading 12% up in pre-market after HC Wainwright initiated Buy-rated coverage
Neurosense Therapeutics is trading 11.93% up at $0.46 after HC Wainwright & Co. initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price...
🟢 Neurosense Therapeutics Surges in Pre-Market on HC Wainwright & Co. 'Buy' Rating and Redesigned PrimeC ALS Strategy
- Neurosense Therapeutics is trading 7.32% up in pre-market at $0.44 following HC Wainwright & Co. initiating coverage with a 'Buy' rating and an $8.00 price...
NeuroSense Rewrites Its ALS Playbook on a Shoestring — But Can a $0.45 Stock Outrun a September Delisting Clock?
Shares of NeuroSense Therapeutics surged 7.1% to $0.45 after the micro-cap biotech unveiled a redesigned, three-pronged strategy to push its lead ALS drug...
🟢 Neurosense Therapeutics is trading 7.09% up today after an accelerated, capital-efficient PrimeC strategy for ALS
Neurosense Therapeutics is trading 7.09% up at $0.45 after its August 31 announcement of an accelerated, capital-efficient PrimeC development strategy for...
NeuroSense Fast-Tracks PrimeC Development, Cutting Costs for ALS Drug Approval
NeuroSense Therapeutics has redesigned its development plan for PrimeC to treat amyotrophic lateral sclerosis (ALS). The new strategy replaces a single large...
🟢 Neurosense Therapeutics is trading 13.23% up today in pre-market; catalyst remains unclear
Neurosense Therapeutics is trading 13.23% higher at $0.48 after rising from the August 28 close of $0.42, with no clear catalyst identified. - No fresh...
🟢 Neurosense Therapeutics is trading 7% up in pre-market with no clear catalyst identified
Neurosense Therapeutics is trading 7.04% up at $0.45, with no fresh company-specific announcement for August 31, 2026 identified. - It reached $0.42 at the...
🟢 Neurosense Therapeutics is trading 7.12% up today
Neurosense Therapeutics is trading 7.12% up at $0.45, extending gains from the August 27 close of $0.44 and August 26 close of $0.41. - No fresh...
🟢 Neurosense Therapeutics is trading 5.16% up today amid stronger biotechnology sentiment
Neurosense Therapeutics is trading 5.16% up at $0.43, extending the August 26, 2026 close of $0.41 after a 6.98% gain, amid stronger biotechnology sentiment...
🟢 Neurosense Therapeutics is trading 13.1% up today amid biotech-sector strength
Neurosense Therapeutics is trading 13.1% up at $0.43, with the move appearing primarily supported by biotechnology-sector strength. - XBI is up 2.06% during...
🟢 Neurosense Therapeutics is trading 6.96% up today as XBI gains 2.06%
Neurosense Therapeutics is trading 6.96% up at $0.41, supported primarily by a broader biotech-sector rally, with XBI up 2.06% during the regular session. -...
🟢 Neurosense Therapeutics is trading 6.72% up in pre-market — no confirmed company-specific catalyst
Neurosense Therapeutics is trading 6.72% up at $0.41 after an overnight move with no confirmed company-specific catalyst. - A special shareholder meeting is...
🟢 Neurosense Therapeutics is trading 5.57% up in after-hours trading amid broader biotech strength
Neurosense Therapeutics is trading 5.57% up now at $0.40 amid broader biotech-sector momentum, with XBI up 2.06% and no confirmed company-specific announcement...
🟢 Neurosense Therapeutics is trading 6.37% up today as XBI gains 2.06%
Neurosense Therapeutics is trading 6.37% up now at $0.40, with the advance best explained by broader biotech-sector strength as XBI rises 2.06%. - No...
🟢 Neurosense Therapeutics is trading 5.16% up in pre-market with no confirmed fresh catalyst
Neurosense Therapeutics is trading 5.16% up in pre-market at $0.40, after closing at $0.38 on August 21, 2026, with no confirmed fresh catalyst identified. -...
🟢 Neurosense Therapeutics is trading 11.30% up today after August 20 selloff
Neurosense Therapeutics is trading 11.30% up at $0.39 after rebounding from its August 20 close of $0.35. - Shares fell 11.96% on August 20. - No new...
🔴 Neurosense Therapeutics is trading 12.04% down today amid delays securing Phase 3 financing
Neurosense Therapeutics is trading 12.04% down now at $0.35 after investors continued reacting to disclosed delays in securing financing for the Phase 3...